Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL381094 | 1.00 | HDAC4 (0.41) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL381542 | 0.92 | NAMPT (0.36) | — | |
| SCHEMBL381543 | 0.92 | NAMPT (0.36) | — | |
| SCHEMBL380482 | 0.90 | HDAC4 (0.41) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL380481 | 0.90 | HDAC4 (0.41) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL416496 | 0.90 | GPR119 (0.44) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL416495 | 0.90 | GPR119 (0.44) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL210630 | 0.89 | KMT2A (0.48) | HDAC4KMT2AMEN1TP53GPR119 | |
| SCHEMBL13031218 | 0.88 | MET (0.36) | ABL1 | |
| SCHEMBL13072734 | 0.88 | HTR2B (0.37) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049513-B1 | PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2049513-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| WO-2007127901-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | HDAC4 1717/4885KMT2A 1602/4885MEN1 3048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.